Hepatotoxicity and tuberculosis treatment outcomes in chronic liver disease.

Brett D Edwards Henry MahNatasha F SaburSarah K Brode

Published in: Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada (2023)

The risk of DILI is high, especially with the use of isoniazid, in patients with TB and chronic liver disease. This risk can be effectively mitigated with no difference in treatment outcomes in the presence of cirrhosis.

Keyphrases

mycobacterium tuberculosis
drug induced
pulmonary tuberculosis
emergency department
hiv aids
hepatitis c virus